Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells 

 

RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells
February 8, 2013 - (PR Newswire) - "RNL BIO CO LTD announced today the filing of an Investigational New Drug application with the Korean Food and Drug Administration to initiate clinical trials phase II and III assessing the company's RNL-Astrostem™ stem cell drug in patients with cerebral palsy." Read Full Press Release

 

Posted on 14-Feb-13 by Gallerno, Jacob
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: